COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy



Ryan Allway

February 3rd, 2021

Psychedelics


COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has shared details of its comprehensive and rigorous therapist training programme for psilocybin therapy, in a paper jointly written with a group of academic researchers, and published in Frontiers in Psychiatry today. The programme sets out a formal and scalable methodology for psychological support in psilocybin therapy. It is currently being used to train therapists taking part in COMPASS’s phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression, as approved by the US Food and Drug Administration (FDA), as part of COMPASS’s Investigational New Drug (IND) application.

In psilocybin therapy, patients are given a dose of psilocybin, a psychedelic substance, in conjunction with psychological support from specially trained therapists. COMPASS developed the therapist training programme alongside leading experts in mental health and psychedelic research, including William A Richards (Johns Hopkins Bayview Medical Center, US), Elizabeth Nielson (NYS Psychiatric Institute, NYU School of Medicine, US), Riikka Ajantaival (Clinical Research Institute, Helsinki University Central Hospital, Finland), Peter Gasser (private practice, Switzerland), Sara J Tai (University of Manchester, UK), Brian D Richards (Johns Hopkins Bayview Medical Center, Sheppard and Enoch Pratt Hospital, and Aquilino Cancer Center, US), and Frederick Reinholdt (King’s College London, UK). The programme uses a new and manualised approach drawing from evidence-based psychotherapeutic approaches, and currently comprises four components: an online learning platform; in-person training; applied clinical training; and ongoing individual mentoring and professional development.

In previous psilocybin studies, the approach to psychological support often varied between research sites, making it difficult to replicate and distinguish the specific effects of psilocybin from concurrent therapeutic interventions. Equally, training in the provision of psychological support had not been defined and evaluated. This manualised training programme begins to address this gap and is the start of a process that will continue to be refined and adapted as clinical trials of psilocybin therapy progress.

Dr William A Richards, a psychologist and research affiliate in the Psychiatry Department of the Johns Hopkins University School of Medicine, Bayview Medical Center, and a co-author of the paper, said, “The psychological support is an integral element of psilocybin therapy and must be provided by trained therapists. The development of a structured and formalised training programme aims to ensure we deliver psilocybin therapy in a way that considers physical and psychological safety, with consistently high quality support.”

Therapists who participated in the training reported that the combination of didactic and experiential learning helped them to build conceptual understanding and develop their skills in the therapeutic approach. From the programme feedback, the clinical training and engagement in participant care, under the guidance of experienced therapists, were considered to be the most beneficial and challenging aspects of the training.

Ekaterina Malievskaia, Chief Innovation Officer and Co-founder, COMPASS Pathways, said, “Psilocybin therapy has the potential to make a difference to millions of people suffering with mental health challenges, and our priority is to develop evidence-based innovations that are safe and effective for patients. High quality clinical training for therapists is an essential part of this. Our training programme is the result of early and ongoing collaboration with many experts and we are grateful for all their contributions. We will continue to evolve our training programme as we progress COMP360 psilocybin therapy through clinical trials. We hope that this first step encourages collaboration among therapist training providers, as we work towards bringing psilocybin therapy to all who might benefit.”

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Latest posts